2,5-Diamino-6-((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)hexanoic acid

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 2,5-Diamino-6-((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)hexanoic acid
• 英文别名: 2,5-diamino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hexanoic acid
• 化学式: C₁₅H₂₃N₇O₅
• 分子量: 381.39
• InChiKey: LMXOHSDXUQEUSF-LWCRYBRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  209
• 氢给体数：
  6
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2,5-Diamino-6-((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)hexanoic acid 生成 3-amino-6-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]piperidin-2-one
  参考文献：
  名称：

  FLORENT, J.;LUNEL, J.;MANCY-COURTILLET, D.

  摘要：

  DOI：

文献信息

• Compositions and methods for diagnosis and treatment of prostate cancer
  申请人：Mounir Zineb

  公开号：US10479997B2

  公开（公告）日：2019-11-19

  The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.

  本发明提供了用于治疗TMPRSS2:ERG阳性前列腺癌受试者的新型个性化疗法、试剂盒、可传输的信息形式和方法。我们还提供了试剂盒、筛选候选 PRMT5 抑制剂的方法以及相关的治疗方法。
• Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
  申请人：The Wistar Institute of Anatomy and Biology

  公开号：US10987353B2

  公开（公告）日：2021-04-27

  In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

  在一些实施方案中，公开了癌症等疾病的治疗方法，包括药物组合物和使用药物组合物治疗癌症的方法，其中癌细胞过度表达精氨酸甲基转移酶CARM1。在一些实施方案中，所公开的治疗方法包括向受试者（包括人类受试者）施用治疗有效剂量的泽斯特同源增强子2（EZH2）抑制剂的步骤，其中受试者的癌细胞过度表达精氨酸甲基转移酶CARM1。 在一些实施方案中，EZH2抑制剂与铂类抗肿瘤药物联合施用。
• FLORENT, J.;LUNEL, J.;MANCY-COURTILLET, D.
  作者：FLORENT, J.、LUNEL, J.、MANCY-COURTILLET, D.

  DOI：——

  日期：——
• INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES
  申请人：Novartis AG

  公开号：EP3191592A1

  公开（公告）日：2017-07-19
• COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
  申请人：Novartis AG

  公开号：EP3227446A1

  公开（公告）日：2017-10-11